Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Kiromic BioPharma, Inc.
< Previous
1
2
Next >
Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival
February 18, 2025
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01
January 21, 2025
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01
December 12, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation
December 03, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01
October 08, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial
October 01, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
September 19, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation
September 19, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma’s Deltacel Receives FDA Fast Track Designation
August 14, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
August 09, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01
August 01, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase
July 18, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
June 20, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
June 06, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
May 29, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
May 20, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
April 24, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
April 02, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
March 19, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
March 01, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
February 28, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
February 14, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
January 29, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
January 05, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
December 14, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces Uplisting to OTCQB Market
November 16, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
OTC
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
November 09, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
OTC
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
October 23, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
OTC
Kiromic BioPharma Welcomes Two New Directors to its Board
July 24, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
May 01, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.